...
mrkr-img

Marker Therapeutics Inc, Common Stock

MRKR

NAQ

$3.8

+$0.07

(1.88%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$33.28M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
39.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.49
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.44 L
$6.16 H
$3.8

About Marker Therapeutics Inc, Common Stock

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMRKRSectorS&P500
1-Week Return-6.63%-2.12%-3%
1-Month Return19.5%-3.42%-0.73%
3-Month Return29.25%-11.13%2.87%
6-Month Return-15.37%-5.74%7.17%
1-Year Return-1.3%3.97%25.31%
3-Year Return-63.11%1.05%28.38%
5-Year Return-87.21%34.37%81.89%
10-Year Return-86.81%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue213.19K466.79K1.24M9.00M3.31M[{"date":"2019-12-31","value":2.37,"profit":true},{"date":"2020-12-31","value":5.18,"profit":true},{"date":"2021-12-31","value":13.79,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":36.77,"profit":true}]
Cost of Revenue12.76M18.88M3.16M3.68M10.42M[{"date":"2019-12-31","value":67.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":16.75,"profit":true},{"date":"2022-12-31","value":19.49,"profit":true},{"date":"2023-12-31","value":55.17,"profit":true}]
Gross Profit(12.55M)(18.41M)(1.92M)5.32M(7.11M)[{"date":"2019-12-31","value":-235.75,"profit":false},{"date":"2020-12-31","value":-345.86,"profit":false},{"date":"2021-12-31","value":-36.08,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-133.46,"profit":false}]
Gross Margin(5887.41%)(3944.85%)(154.70%)59.13%(214.60%)[{"date":"2019-12-31","value":-9957.28,"profit":false},{"date":"2020-12-31","value":-6671.86,"profit":false},{"date":"2021-12-31","value":-261.64,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-362.95,"profit":false}]
Operating Expenses22.74M29.35M40.72M38.96M17.89M[{"date":"2019-12-31","value":55.85,"profit":true},{"date":"2020-12-31","value":72.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.68,"profit":true},{"date":"2023-12-31","value":43.94,"profit":true}]
Operating Income(22.53M)(28.89M)(39.48M)(29.95M)(14.58M)[{"date":"2019-12-31","value":-2252880600,"profit":false},{"date":"2020-12-31","value":-2888581200,"profit":false},{"date":"2021-12-31","value":-3947799500,"profit":false},{"date":"2022-12-31","value":-2994578300,"profit":false},{"date":"2023-12-31","value":-1458137800,"profit":false}]
Total Non-Operating Income/Expense2.18M328.48K(2.40M)263.15K986.39K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":15.04,"profit":true},{"date":"2021-12-31","value":-109.69,"profit":false},{"date":"2022-12-31","value":12.05,"profit":true},{"date":"2023-12-31","value":45.17,"profit":true}]
Pre-Tax Income(21.43M)(28.71M)(41.88M)(29.93M)(14.04M)[{"date":"2019-12-31","value":-2142796400,"profit":false},{"date":"2020-12-31","value":-2870607000,"profit":false},{"date":"2021-12-31","value":-4187887100,"profit":false},{"date":"2022-12-31","value":-2993069400,"profit":false},{"date":"2023-12-31","value":-1404222000,"profit":false}]
Income Taxes(1.10M)(179.74K)(5.70K)(15.09K)3.67K[{"date":"2019-12-31","value":-29954.88,"profit":false},{"date":"2020-12-31","value":-4890.94,"profit":false},{"date":"2021-12-31","value":-155.1,"profit":false},{"date":"2022-12-31","value":-410.59,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(20.33M)(28.53M)(41.87M)(29.92M)(14.05M)[{"date":"2019-12-31","value":-2032712200,"profit":false},{"date":"2020-12-31","value":-2852632800,"profit":false},{"date":"2021-12-31","value":-4187317100,"profit":false},{"date":"2022-12-31","value":-2991560500,"profit":false},{"date":"2023-12-31","value":-1404589500,"profit":false}]
Income From Continuous Operations(21.43M)(28.71M)(41.88M)(29.93M)(24.50M)[{"date":"2019-12-31","value":-2142796400,"profit":false},{"date":"2020-12-31","value":-2870607000,"profit":false},{"date":"2021-12-31","value":-4187887100,"profit":false},{"date":"2022-12-31","value":-2993069400,"profit":false},{"date":"2023-12-31","value":-2450390000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(20.33M)(28.53M)(41.87M)(29.92M)(14.05M)[{"date":"2019-12-31","value":-2032712200,"profit":false},{"date":"2020-12-31","value":-2852632800,"profit":false},{"date":"2021-12-31","value":-4187317100,"profit":false},{"date":"2022-12-31","value":-2991560500,"profit":false},{"date":"2023-12-31","value":-1404589500,"profit":false}]
EPS (Diluted)(4.70)(6.20)(5.30)(3.58)(1.10)[{"date":"2019-12-31","value":-470,"profit":false},{"date":"2020-12-31","value":-620,"profit":false},{"date":"2021-12-31","value":-530,"profit":false},{"date":"2022-12-31","value":-358,"profit":false},{"date":"2023-12-31","value":-110.16,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MRKR
Cash Ratio 2.60
Current Ratio 3.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MRKR
ROA (LTM) -40.87%
ROE (LTM) -71.74%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MRKR
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MRKR
Trailing PE NM
Forward PE NM
P/S (TTM) 8.93
P/B 4.86
Price/FCF 28
EV/R 3.41
EV/Ebitda NM

FAQs

What is Marker Therapeutics Inc share price today?

Marker Therapeutics Inc (MRKR) share price today is $3.8

Can Indians buy Marker Therapeutics Inc shares?

Yes, Indians can buy shares of Marker Therapeutics Inc (MRKR) on Vested. To buy Marker Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRKR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Marker Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Marker Therapeutics Inc (MRKR) via the Vested app. You can start investing in Marker Therapeutics Inc (MRKR) with a minimum investment of $1.

How to invest in Marker Therapeutics Inc shares from India?

You can invest in shares of Marker Therapeutics Inc (MRKR) via Vested in three simple steps:

  • Click on Sign Up or Invest in MRKR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Marker Therapeutics Inc shares
What is Marker Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Marker Therapeutics Inc (MRKR) is $6.16. The 52-week low price of Marker Therapeutics Inc (MRKR) is $2.44.

What is Marker Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Marker Therapeutics Inc (MRKR) is

What is Marker Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Marker Therapeutics Inc (MRKR) is 4.86

What is Marker Therapeutics Inc dividend yield?

The dividend yield of Marker Therapeutics Inc (MRKR) is 0.00%

What is the Market Cap of Marker Therapeutics Inc?

The market capitalization of Marker Therapeutics Inc (MRKR) is $33.28M

What is Marker Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Marker Therapeutics Inc is MRKR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top